Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4A3 | P38919 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.51 |
| ▸ | RHEB | Q15382 | 4/20 | 0.49 |
| ▸ | IDO1 | P14902 | 3/20 | 0.46 |
| ▸ | TDO2 | P48775 | 3/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29655546 | 1.00 | EIF4A3 (0.63) | EIF4A3KDM4EHSD17B10HPGDLMNA | |
| SCHEMBL30536689 | 0.86 | EIF4A3 (0.49) | EIF4A3KDM4EHSD17B10HPGDLMNA | |
| SCHEMBL24448445 | 0.85 | EIF4A3 (0.47) | EIF4A3KDM4EHSD17B10HPGDLMNA | |
| SCHEMBL30147573 | 0.85 | EIF4A3 (0.47) | EIF4A3KDM4EHSD17B10HPGDLMNA | |
| SCHEMBL16234661 | 0.85 | EIF4A3 (0.51) | EIF4A3KDM4EHSD17B10HPGDLMNA | |
| SCHEMBL30067362 | 0.85 | EIF4A3 (0.47) | EIF4A3KDM4EHSD17B10HPGDLMNA | |
| SCHEMBL15515831 | 0.84 | GRIN1 (0.70) | EIF4A3KDM4EHSD17B10HPGDLMNA | |
| SCHEMBL21624049 | 0.84 | KDM4E (0.51) | EIF4A3KDM4EHSD17B10HPGDLMNA | |
| SCHEMBL20505503 | 0.84 | EIF4A3 (0.54) | EIF4A3KDM4EHSD17B10HPGDLMNA | |
| SCHEMBL29974385 | 0.84 | GRIN1 (0.70) | EIF4A3KDM4EHSD17B10HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718633-B2 | Indole compounds, process for the preparation and use thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2023-08-08 | — | — | US | claimed |
| US-20210238204-A1 | INDOLE COMPOUNDS, PROCESS FOR THE PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2021-08-05 | — | — | US | claimed |
| US-8242275-B2 | Bicyclic pyrazole compounds as antibacterial agents | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-14 | — | — | US | claimed |
| US-7842810-B2 | 2,3-Dihydro-benzo[1,4]dioxine-6-carboxylic acid [2-(6-methoxy-quinolin-4-yl)-4,5,6,7-tetrahydro-2H-indazol-5-yl]-amide | JANSSEN PHARMACEUTICA, NV (BE) | 2010-11-30 | — | — | US | claimed |
| US-20100280240-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | ALLISON BRETT D | 2010-11-04 | — | — | US | claimed |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AG (DE) | 2009-01-22 | — | — | US | claimed |
| EP-1863483-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | Janssen Pharmaceutica, N.V. (BE) | 2007-12-12 | — | — | EP | claimed |
| US-20060223810-A1 | Bicyclic pyrazole compounds as antibacterial agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-05 | — | — | US | claimed |
| WO-2006105289-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-05 | — | — | WO | claimed |
| US-20260125366-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12540141-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| EP-4635972-A2 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4612156-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4605386-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| WO-2008152099-A2 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-18 | — | — | WO | disclosed |
| US-20080027122-A1 | Indole derivatives | TANABE SEIYAKU CO., LTD. | 2008-01-31 | — | — | US | disclosed |
| WO-2008013322-A1 | 1- (-D-GLYCOPYRANOSYL) - 3 - (4-CYCLOPROPYLPHENYLMETHYL) - 4 - HALOGENO INDOLE DERIVATIVES AND USE THEREOF AS SGLT INHIBITORS. | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-01-31 | — | — | WO | disclosed |
| EP-1863483-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | Janssen Pharmaceutica, N.V. (BE) | 2007-12-12 | — | — | EP | disclosed |
| US-20060223810-A1 | Bicyclic pyrazole compounds as antibacterial agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-05 | — | — | US | disclosed |
| WO-2006105289-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027122-A1 | Indole derivatives | SLC5A1, SLC5A2, SLC5A11 | EIF4A3 3034/4885KDM4E 1709/4885HSD17B10 750/4885 |
| US-20060223810-A1 | Bicyclic pyrazole compounds as antibacterial agents | NOD2, BAK1, CASP3 | EIF4A3 769/4885KDM4E 4629/4885HSD17B10 3644/4885 |
| US-20100280240-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | NOD2, BAK1, CASP3 | EIF4A3 769/4885KDM4E 4629/4885HSD17B10 3644/4885 |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | PTGER2, PTGER1, PTGDR2 | EIF4A3 3270/4885KDM4E 3048/4885HSD17B10 297/4885 |
| US-11718633-B2 | Indole compounds, process for the preparation and use thereof | IDO1, IDO2, INMT | EIF4A3 3850/4885KDM4E 1740/4885HSD17B10 1445/4885 |
| US-12540141-B2 | Spiropyrrolidine derived antiviral agents | ACE2, NR3C2, ACE | EIF4A3 352/4885KDM4E 3753/4885HSD17B10 308/4885 |
| US-20210238204-A1 | INDOLE COMPOUNDS, PROCESS FOR THE PREPARATION AND USE THEREOF | IDO1, IDO2, INMT | EIF4A3 3850/4885KDM4E 1740/4885HSD17B10 1445/4885 |
| US-20260125366-A1 | METHODS FOR TREATING CANCER | AKT2, AKT3, PIK3R5 | EIF4A3 528/4885KDM4E 3679/4885HSD17B10 1685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.